INVESTIGATION OF THE RELATIONSHIP OF TNFRSF11A
GENE POLYMORPHISMS WITH BREAST CANCER
DEVELOPMENT AND METASTASIS RISK IN PATIENTS
WITH BRCA1 OR BRCA2 PATHOGENIC VARIANTS
LIVING IN THE TRAKYA REGION OF TURKEY
Özdemir K, Gürkan H, Demir S, Atli E, Özen Y, Sezer A, Tunçbilek N, Çicin İ
*Corresponding Author: Hakan Gürkan, MD, PhD, Department of Medical Genetics, Genetic Diseases
Diagnosis Center, Trakya University Faculty of Medicine, Balkan Campus, 22030 Edirne, Turkey. Tel:
+90-533-218-8005. Fax: +90-284-235-7641. Email: dr_hakangurkan@yahoo.de, hgurkan@trakya.edu.tr
page: 49
|
|
REFERENCES
1. Yararbas K, Atalay PB. Association of E-selectin
S128R polymorphism with hereditary breast carcinoma
susceptibility in Turkish patients without
BRCA1/2 germline mutations. Balkan J Med Genet.
2018; 21(1): 27-32.
2. Armstrong N, Ryder S, Forbes C, Ross J, Quek RGw.
A systematic review of the international prevalence
of BRCA mutation in breast cancer. Clin Epidemiol.
2019;11:543-561.
3. Hughes DC. Use of association studies to define genetic
modifiers of breast cancer risk in BRCA1 and
BRCA2 mutation carriers. Fam Cancer. 2008; 7(3):
233-244.
4. Wittersheim M, Büttner R, Markiefka B. Genotype/
phenotype correlations in patients with hereditary
breast cancer. Breast Care (Basel). 2015; 10(1): 22-
26.
5. Hughes DJ, Ginolhac SM, Coupier I, Barjhoux L,
Gaborieau V, Bressac-de-Paillerets B, et al. Breast
cancer risk in BRCA1 and BRCA2 mutation carriers
and poly-glutamine repeat length in the AIB1 gene.
Int J Cancer. 2005; 117(2): 230-233.
6. Pristauz G, Petru E, Stacher E, Geigl JB, Schwarzbraun
T, Tsybrovskyy O, et al. Androgen receptor
expression in breast cancer patients tested for BRCA1
and BRCA2 mutations. Histopathology. 2010; 57(6):
877-884.
7. Ricks-Santi LJ, Sucheston LE, Yang Y, Freudenheim
JL, Isaacs CJ, Schwartz MD, et al. Association of
Rad51 polymorphism with DNA repair in BRCA1
mutation carriers and sporadic breast cancer risk.
BMC Cancer. 2011; 11: 278.
8. Bonifaci N, Palafox M, Pellegrini P, Osorio A, Benítez
J, Peterlongo P, et al. Evidence for a link between
TNFRSF11A and risk of breast cancer. Breast Cancer
Res Treat. 2011; 129(3): 947-954.
9. Kim K, Kim JH, Lee J, Jin HM, Lee SH, Fisher DE,
et al. Nuclear factor of activated T cells c1 induces
osteoclast-associated receptor gene expression during
tumor necrosis factor-related activation-induced
cytokine-mediated osteoclastogenesis. J Biol Chem.
2005; 280(42): 35209-35216.
10. Geerts D, Chopra C, Connelly L. Osteoprotegerin:
Relationship to breast cancer risk and prognosis.
Front Oncol. 2020; 10: 462.
11. Boyce BF, Xing L. Biology of RANK, RANKL, and
osteoprotegerin. Arthritis Res Ther. 2007; 9(Suppl 1):
S1.
12. Willard D, Chen WJ, Barrett G, Blackburn K, Bynum
J, Consler T, et al. Expression, purification, and
characterization of the human receptor activator of
NF-kappaB ligand (RANKL) extracellular domain.
Protein Expr Purif. 2000; 20(1): 48-57.
13. Walsh MC, Choi Y. Biology of the RANKL-RANKOPG
system in immunity, bone, and beyond. Front
Immunol. 2014; 5: 511.
14. Sigl V, Jones LP, Penninger JM. RANKL/RANK:
From bone loss to the prevention of breast cancer.
Open Biol. 2016; 6(11): 160230. 15. Kiesel L, Kohl A. Role of the RANK/RANKL pathway
in breast cancer. Maturitas. 2016; 86: 10-16.
16. Renema N, Navet B, Heymann MF, Lezot F, Heymann
D. RANK-RANKL signalling in cancer. Biosci
Rep. 2016; 36(4): e00366.
17. Sigl V, Owusu Boaitey K, Joshi PA, Kavirayani A,
Wirnsberger G, Novatchkova M, et al. RANKL/
RANK control BRCA1 mutation-driven mammary
tumors. Nature. 2016; 26(7): 761-774.
18. Azim HA Jr, Peccatori FA, Brohée S, Branstetter D,
Loi S, Viale G, et al. RANK ligand (RANKL) expression
in young breast cancer patients and during
pregnancy. Breast Cancer Res. 2015; 17: 24.
19. van Dam PA, Verhoeven Y, Trinh XB, Wouters A,
Lardon F, Prenen H, et al. RANK/RANKL signaling
inhibition may improve the effectiveness of checkpoint
blockade in cancer treatment. Crit Rev Oncol
Hematol. 2019; 133: 85-91.
20. Fardmanesh H, Shekari M, Movafagh A, Alizadeh
Shargh S, Poursadegh Zonouzi AA, Shakerizadeh S.
Up-regulation of the double-stranded RNA binding
protein DGCR8 in invasive ductal breast carcinoma.
Gene. 2016; 581(2): 146–151.
21. Toriola AT, Appleton CM, Zong X, Luo J, Weilbaecher
K, Tamimi RM, et al. Circulating receptor
activator of nuclear factor-κB (RANK), RANK ligand
(RANKL), and mammographic density in premenopausal
women. Cancer Prev Res (Phila). 2018;
11(12): 789-796.
22. Lu Y, Liu P, Recker RR, Deng HW, Dvornyk V.
TNFRSF11A and TNFSF11 are associated with age
at menarche and natural menopause in white women.
Menopause. 2010; 17(5): 1048-1054.
23. Chung PY, Beyens G, Riches PL, Van Wesenbeeck
L, de Freitas F, Jennes K, et al. Genetic variation in
the TNFRSF11A gene encoding RANK is associated
with susceptibility to Paget’s disease of bone. Bone
Miner Res. 2010; 25(12): 2592-2605.
24. Lilyquist J, Ruddy KJ, Vachon CM, Couch FJ. Common
genetic variation and breast cancer risk-past,
present, and future. Cancer Epidemiol Biomarkers
Prev. 2018; 27(4): 380-394.
25. Gayán J, Galan JJ, González-Pérez A, Sáez ME, Martínez-
Larrad MT, Zabena C, et al. Genetic structure
of the Spanish population. BMC Genomics. 2010;
11: 326.
26. Ney JT, Juhasz-Boess I, Gruenhage F, Graeber S,
Bohle RM, Pfreundschuh M, et al. Genetic polymorphism
of the OPG gene associated with breast cancer.
BMC Cancer. 2013; 13: 40.
27. Rao S, Cronin SJF, Sigl V, Penninger JM. RANKL
and RANK: From mammalian physiology to cancer
treatment. Trends Cell Biol. 2018; 28(3): 213-223.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
